Advancing Neurogenetic Diagnoses Through Long-Read Sequencing
Starting soon · Not applicable
Conditions studied: Neurogenetic Diseases
In brief
Nucleotide repeats emerge as one of the most prolific classes of genetic variations. They have the propensity to in-crease in length across generations, and have been implicated in at least 65 known neurological/ neurodevelop-mental and neuromuscular conditions. Simultaneous analysis of all these nucleotide repeats is now possible through the cutting-edge methodologies recently developed that are the long-read sequencing and the optical genome mapping. Investigator propose to test these methodologies in patients carrying expansions in those repeats and to determine the capacity of these technics to detect novel repeats in patients with no genetic diagnosis yet.
Key facts
- Study ID
- NCT07665554
- Run by
- University Hospital, Bordeaux
- People needed
- 304
- Starts
- 2026-09-01
- Expected to finish
- 2028-09-01
- Last updated by the study team
- 2026-06-24
Who can join
Age: 6 and older, up to 60. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- All participants :
- Participants affiliated with or beneficiaries of a social security scheme
- Participants who speak French
- Participants aged ≥ 6 and ≤ 60 years
- For patients requiring a new sample:
- Free and informed consent, signed by the parents or the holder of parental authority for patients under the age of 18
- Free and informed consent, signed by the patient's representative for adults under guardianship
- Free and informed consent, signed by the adult patient
- For diagnosed patients :
- DeoxyriboNucleic Acid (DNA) sample from a subject carrying a nucleotide repeat expansion in one of the selected genes.
- DNA available in sufficient quantity (5-10 µg) or patient agreeing to a blood draw from which DNA will be extracted.
- DNA extraction methods known and validated by the steering committee (see paragraph 7).
- For participants from undiagnosed families :
- o Index cases:
- Patient affected by a neurological disease candidate for these repeats, for which genomic data did not reveal mutations or expansions in known genes.
- Patient whose DNA is already available and whose extraction method is known and validated by the steering committee or patient whose DNA is not available but who agrees to a blood draw.
- Patient willing to undergo a skin biopsy if not previously obtained.
- Patient with no family members affected by any of the neurological diseases candidate for these repeats, i.e., genomic data do not reveal mutations or expansions in known genes.
- Patient from a family in which at least one affected and one unaffected member agree to partici-pate in the study by providing a sample, or whose DNA is already available and extracted using a method known and validated by the steering committee.
- For all related members of undiagnosed families who have agreed to participate:
- Have at least two other family members who have agreed to participate in the study.
- Agree to provide a blood sample or have DNA already available in sufficient quantity and extracted using a method known and validated by the steering committee.
- Patient willing to undergo a skin biopsy if not previously obtained.
- Be affected by a neurological disease candidate for these repeats, for which genomic data did not reveal mutations or expansions in known genes, or be unaffected and have had a neurological examination showing no signs related to any of the neurological diseases candidate for these repeats.
- For controls :
You may not qualify if…
- For all participants:
- Refusal to participate in research: Refusal to provide informed consent or opposition to the use of these samples.
- By the parents or the holder of parental authority for patients under the age of 18
- By the patient's representative for adults under guardianship
- By the adult patient This opposition from the patient must be communicated to the site investigator within a maximum of one month after the information note has been sent. If the letter confirming consent is returned due to an incorrect address, the patient will not be included.
- Degraded DNA or average size < 30 kb
Where it is running
- CHU Bordeaux - Hôpital Pellegrin — Bordeaux, France, France
- AP-HP Hôpital Pitié-Salpêtrière — Paris, France, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.